Does acromegaly enhance mortality?

Reviews in Endocrine and Metabolic Disorders

Volumn 9, Issue 1, 2008, Pages 33-39

  Ayuk, John ^a   Sheppard, Michael C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acromegaly; Growth hormone; Hypopituitarism; Mortality; Pituitary; Radiotherapy

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; COLON CANCER; DIABETES MELLITUS; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOPITUITARISM; LIFE EXPECTANCY; METABOLIC DISORDER; POPULATION; REVIEW;

ACROMEGALY; GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; PROGNOSIS;

EID: 39149110919     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-007-9067-8     Document Type: Review

References (49)

1. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970;39:1-16.
2. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71-9.
3. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987;26:481-512.
4. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-9.
5. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102.
6. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4.
7. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86-91.
8. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613-7.
9. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74.
10. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439-46.
11. Evans HM, Briggs AH, Dixon JS. In: Harris GW, Donovan BT, editors. The pituitary gland. London: Butterworth; 1966. p. 439.
12. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327-35.
13. Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest 1993;16:181-7.
14. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-8.
15. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
16. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789-96.
17. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90:4081-6.
18. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
19. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.
20. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40.
21. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8.
22. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-72.
23. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75-81.
24. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-31.
25. Erfurth EM, Bulow B, Eskilsson J, Hagmar L. High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Growth Horm IGF Res 1999;9(Suppl A):21-4.
26. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646-52.
27. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf) 1995;42:417-23.
28. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001;86:1645-52.
29. Wabitsch M, Hauner H, Heinze E, Teller WM. The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Metabolism 1995;44:45-9.
30. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
31. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801-31.
32. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-16.
33. Peacey SR, Toogood AA, Shalet SM. Hypothalamic dysfunction in "cured" acromegaly is treatment modality dependent. J Clin Endocrinol Metab 1998;83:1682-6.
34. Barkan AL. Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 2003;58:132-5.
35. Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-8.
36. Flickinger JC, Nelson PB, Taylor FH, Robinson A. Incidence of cerebral infarction after radiotherapy for pituitary adenoma. Cancer 1989;63:2404-8.
37. Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002;57:713-7.
38. O'Connor MM, Mayberg MR. Effects of radiation on cerebral vasculature: a review. Neurosurgery 2000;46:138-49.
39. Wass JA. Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol (Oxf) 2003;58:128-31.
40. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer 1991;68:1673-7.
41. Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86:2929-34.
42. Jenkins PJ, Fairclough PD. Colorectal neoplasia in acromegaly. Clin Endocrinol (Oxf) 2001;55:727-9.
43. Renehan AG, Odwyer ST, Shalet SM. Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 2001;55:731-3.
44. Perry I, Stewart PM, Kane K. Colorectal screening guidelines in acromegaly. Gut 2003;52:1387.
45. Renehan AG, O'Connell J, O'Halloran D, Shanahan F, Potten CS, O'Dwyer ST, et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003;35:712-25.
46. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193-9.
47. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4:239-49.
48. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003;26:1242-7.
49. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13:185-92.